Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-906-4600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable
Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions
What is Pulse Biosciences' stock symbol?
Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."
How were Pulse Biosciences' earnings last quarter?
Pulse Biosciences Inc (NASDAQ:PLSE) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. View Pulse Biosciences' Earnings History.
When is Pulse Biosciences' next earnings date?
What price target have analysts set for PLSE?
1 Wall Street analysts have issued 12 month price objectives for Pulse Biosciences' shares. Their forecasts range from $27.00 to $27.00. On average, they anticipate Pulse Biosciences' stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price. View Analyst Price Targets for Pulse Biosciences.
What is the consensus analysts' recommendation for Pulse Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulse Biosciences.
Has Pulse Biosciences been receiving favorable news coverage?
Media coverage about PLSE stock has been trending very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulse Biosciences earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Pulse Biosciences.
Who are some of Pulse Biosciences' key competitors?
Some companies that are related to Pulse Biosciences include AtriCure (ATRC), Silk Road Medical (SILK), Tactile Systems Technology (TCMD), Shockwave Medical (SWAV), Cryolife (CRY), Anika Therapeutics (ANIK), Orthofix Medical (OFIX), Luminex (LMNX), Intersect ENT (XENT), LeMaitre Vascular (LMAT), Axonics Modulation Technologies (AXNX), Antares Pharma (ATRS), Cerus (CERS), AngioDynamics (ANGO) and Orthopediatrics (KIDS).
What other stocks do shareholders of Pulse Biosciences own?
Who are Pulse Biosciences' key executives?
Pulse Biosciences' management team includes the folowing people:
- Mr. Darrin R. Uecker, Pres, CEO & Director (Age 53)
- Mr. Brian B. Dow, CFO, Sr. VP of Fin. & Admin., Treasurer and Sec. (Age 50)
- Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 59)
- Dr. Richard Nuccitelli Ph.D., Chief Science Officer
- Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
When did Pulse Biosciences IPO?
(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.
Who are Pulse Biosciences' major shareholders?
Pulse Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Griffin Asset Management Inc. (0.23%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh and Robert W Duggan. View Institutional Ownership Trends for Pulse Biosciences.
Which major investors are selling Pulse Biosciences stock?
How do I buy shares of Pulse Biosciences?
Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pulse Biosciences' stock price today?
One share of PLSE stock can currently be purchased for approximately $14.37.
How big of a company is Pulse Biosciences?
Pulse Biosciences has a market capitalization of $298.46 million. The company earns $-37,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe.View Additional Information About Pulse Biosciences.
What is Pulse Biosciences' official website?
How can I contact Pulse Biosciences?
Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]
MarketBeat Community Rating for Pulse Biosciences (NASDAQ PLSE)
MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe PLSE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLSE will underperform the S&P 500 over the long term. You may vote once every thirty days.
